LivaNova Unveils Strategic Roadmap Targeting High-Single-Digit Revenue Growth, Operating Margin Expansion, and Investment in Core and Emerging Markets by 2030
LivaNova plc has outlined a comprehensive strategic roadmap and long-range financial plan, targeting revenue and earnings-per-share growth through 2030. The company aims to leverage its leadership positions in the Epilepsy and Cardiopulmonary businesses to drive predictable growth, expand margins, and generate consistent cash flow. Key elements of the strategy include maximizing core business performance, scaling the Obstructive Sleep Apnea (OSA) segment, and maintaining potential upside in Difficult-to-Treat Depression $(DTD)$, pending Centers for Medicare & Medicaid Services $(CMS)$ coverage. LivaNova's Cardiopulmonary business will focus on capitalizing on replacement cycles, introducing a next-generation oxygenator by 2028, and expanding recurring revenues through software and services. Financial targets include achieving an adjusted annual operating margin above 20% over the next three years, reaching the high twenties by 2030, maintaining adjusted free cash flow conversion above 80%, and delivering a low double-digit to mid-teens earnings-per-share compound annual growth rate.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112935100) on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.